Global Biologics Contract Development and Manufacturing Organizations Growth Opportunities

Global Biologics Contract Development and Manufacturing Organizations Growth Opportunities

Asset Co-Development with Clinical-stage Biopharmaceutical Companies and Disruptive Technologies Present Future Growth Potential

RELEASE DATE
17-Jun-2021
REGION
North America
Research Code: MG0C-01-00-00-00
SKU: HC03420-NA-MT_25509

$4,950.00

Special Price $4,455.00 save 10 %

In stock
SKU
HC03420-NA-MT_25509

$4,950.00

$4,455.00 save 10 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

This study presents Frost & Sullivan’s overall market and segment-wise revenue forecasts of the global biologics contract development and manufacturing organizations (bio-CDMO) market. It also highlights key growth opportunities for bio-CDMO market participants based on the main evolution in their business models and strategic approaches, as well as those of the pharmaceutical sponsors. The study segments the market by product (drug substance and drug product), cell line (mammalian, microbial, and viral vectors and other modalities) and service (clinical and commercial) types. The market forecasts in this report are for 2020–2026. They capture key market developments, such as capacity expansions, mergers, acquisitions, and expanding services offerings set to impact the overall bio-CDMO market growth.

Other discussions on the global bio-CDMO market include:

•     Impact of strategic imperatives on the industry
•     Growth drivers and restraints
•     Comprehensive insights on its competitive landscape
•     Revenue share estimates of top market participants
•     A strategic analysis of market developments regarding services offerings and business models
•     Growth opportunities centered on single-use technology in the development and manufacturing of personalized medicine, COVID-19 vaccine scale-up partnerships, assets co-development with small and midsize pharma companies, and opportunities in China’s domestic biopharma market

Author: Deepak Jayakumar

RESEARCH: INFOGRAPHIC

This infographic presents a brief overview of the research, and highlights the key topics discussed in it.
Click image to view it in full size

Table of Contents

Why is it Increasingly Difficult to Grow?

The Strategic Imperative 8™

The Impact of the Top Three Strategic Imperatives on the Biologics Contract Development and Manufacturing Organizations Industry

Growth Opportunities Fuel the Growth Pipeline Engine™

Bio-CDMO Market Scope of Analysis

Bio-CDMO Market Segmentation by Product Type

Bio-CDMO Market Segmentation by Cell Line Type

Bio-CDMO Market Segmentation by Service Type

Key Competitors for the Bio-CDMO Market

Key Growth Metrics for the Global Bio-CDMO Market

Growth Drivers for Bio-CDMO Market

Growth Restraints for the Bio-CDMO Market

Forecast Framework, Bio-CDMO Market

Forecast Methodology, Bio-CDMO Market

Forecast Assumptions and Considerations, Bio-CDMO Market

Revenue Forecast, Bio-CDMO Market

Revenue Forecast Analysis, Bio-CDMO Market

Revenue Forecast by Product Type, Bio-CDMO Market

Revenue Forecast Analysis by Product Type, Bio-CDMO Market

Revenue Forecast by Cell Line Type, Bio-CDMO Market

Revenue Forecast Analysis by Cell Line Type, Bio-CDMO Market

Revenue Split by Service Type, Bio-CDMO Market

Revenue Forecast Analysis by Service Type, Bio-CDMO Market

Regional Analysis, Bio-CDMO Market

Competitive Environment, Bio-CDMO Market

Revenue Share, Bio-CDMO Market

Revenue Share Analysis, Bio-CDMO Market

Top Bio-CDMOs Edging Closer to a Comprehensive One-Stop-Shop Service Offering

Growth Avenues, Bio-CDMO Industry

Transitions in Bio-CDMO Business Models

Growth Opportunity Analysis Mapping, Bio-CDMO Market

Growth Opportunity 1—Adoption of Single-Use Technology for Cell and Gene Therapy Manufacturing

Growth Opportunity 1—Adoption of Single-Use Technology for Cell and Gene Therapy Manufacturing (continued)

Growth Opportunity 2—Capacity-Building Partnerships for COVID-19 Vaccine Manufacturing

Growth Opportunity 2—Capacity-Building Partnerships for COVID-19 Vaccine Manufacturing(continued)

Bio-CDMO Milestones for COVID-19 Vaccine Manufacturing

Growth Opportunity 3—Co-Developing Antibody Therapies with Clinical-stage Biopharma Companies

Growth Opportunity 3—Co-Developing Antibody Therapies with Clinical-stage Biopharma Companies (continued)

Growth Opportunity 4—Addressing Capacity Scale-up Needs of China’s Domestic Biopharma Market

Growth Opportunity 4—Addressing Capacity Scale-up Needs of China’s Domestic Biopharma Market (continued)

China’s Biologics Pipeline

Your Next Steps

Why Frost, Why Now?

List of Exhibits

Legal Disclaimer

Related Research
This study presents Frost & Sullivans overall market and segment-wise revenue forecasts of the global biologics contract development and manufacturing organizations (bio-CDMO) market. It also highlights key growth opportunities for bio-CDMO market participants based on the main evolution in their business models and strategic approaches, as well as those of the pharmaceutical sponsors. The study segments the market by product (drug substance and drug product), cell line (mammalian, microbial, and viral vectors and other modalities) and service (clinical and commercial) types. The market forecasts in this report are for 2020–2026. They capture key market developments, such as capacity expansions, mergers, acquisitions, and expanding services offerings set to impact the overall bio-CDMO market growth. Other discussions on the global bio-CDMO market include: • Impact of strategic imperatives on the industry • Growth drivers and restraints • Comprehensive insights on its competitive landscape • Revenue share estimates of top market participants • A strategic analysis of market developments regarding services offerings and business models • Growth opportunities centered on single-use technology in the development and manufacturing of personalized medicine, COVID-19 vaccine scale-up partnerships, assets co-development with small and midsize pharma companies, and opportunities in Chinas domestic biopharma market Author: Deepak Jayakumar
More Information
No Index No
Podcast No
Author Deepak Jayakumar
Industries Healthcare
WIP Number MG0C-01-00-00-00
Is Prebook No
GPS Codes 9600-B1,9571-B1,99C1-B1,9568-B1,9611-B1